RESEARCH & DEVELOPMENT:

At Smilax, we recognize that Research & Development is vital component for sustainability, growth and long term competitive advantage.

Today Smilax has a pool of over 50 scientists to transform Smilax a completely research driven pharmaceutical company. Our key focus areas are complex APIs, APIs for both regulated and semi regulated markets.

Smilax R&D has core strengths in:

• Design and synthesis of APIs and their intermediates
• Development of Non- infringing processes
• Identification, isolation / synthesis of impurities
• Developing alternate and cost effective processes
• Chiral separations
• Studies on polymorphic forms

Intellectual Property Management:

With an aim to emerge as a major player in regulated markets such as United States and European Union in order to evaluate IP issues. We have set up an Intellectual property management group.

The Company’s competitive advantage is in capturing a large portfolio of approvals, backed up by R&D effort that offers several patented non-infringing processes and intellectual properties, and a cost efficient mega manufacturing environment complying with regulatory authorities.

The process of creating Intellectual wealth starts with judicious product identification, based on technological complexity and emerging opportunities.Intellectual property management deals with-

• Patent assessment
• Interpreting patent claims and handling Infringement issues
• Handling IP related queries
• Finalization of the non-infringing synthetic routes for APIs
• Protecting the company’s inventions across the globe

As a part of internal IP management, Smilax signs a Confidentiality Disclosure Agreement (CDA) to protect all sensitive information before commencing business with its prospective business associates,